TW204349B - - Google Patents
Download PDFInfo
- Publication number
- TW204349B TW204349B TW081103509A TW81103509A TW204349B TW 204349 B TW204349 B TW 204349B TW 081103509 A TW081103509 A TW 081103509A TW 81103509 A TW81103509 A TW 81103509A TW 204349 B TW204349 B TW 204349B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- methyl
- substance
- pharmaceutically acceptable
- amine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 36
- -1 5 — isopropyl-2-methylphenyl Chemical group 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 26
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 25
- 102100024304 Protachykinin-1 Human genes 0.000 claims description 25
- 101800003906 Substance P Proteins 0.000 claims description 25
- 241000124008 Mammalia Species 0.000 claims description 21
- 238000011049 filling Methods 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 19
- 230000002265 prevention Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 7
- 208000025747 Rheumatic disease Diseases 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 7
- 230000002981 neuropathic effect Effects 0.000 claims description 7
- 201000001119 neuropathy Diseases 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 206010047163 Vasospasm Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 230000002518 glial effect Effects 0.000 claims description 6
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- 230000011514 reflex Effects 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 5
- 241000700199 Cavia porcellus Species 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 208000030212 nutrition disease Diseases 0.000 claims description 4
- 208000024335 physical disease Diseases 0.000 claims description 4
- 230000005062 synaptic transmission Effects 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 241000700198 Cavia Species 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 4
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 229960002504 capsaicin Drugs 0.000 claims 2
- 235000017663 capsaicin Nutrition 0.000 claims 2
- 239000007928 intraperitoneal injection Substances 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- IGGJUJBXDYMIBN-UHFFFAOYSA-N 2-benzhydryl-1-azabicyclo[2.2.2]octane Chemical compound C1CN2CCC1CC2C(C=1C=CC=CC=1)C1=CC=CC=C1 IGGJUJBXDYMIBN-UHFFFAOYSA-N 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- KDBJAQOEAOOFBL-UHFFFAOYSA-N CS(=O)(=O)O.N12CC(C(CC1)CC2)N Chemical compound CS(=O)(=O)O.N12CC(C(CC1)CC2)N KDBJAQOEAOOFBL-UHFFFAOYSA-N 0.000 claims 1
- 238000002835 absorbance Methods 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 239000001045 blue dye Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000007799 cork Substances 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- 206010027654 Allergic conditions Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 244000046146 Pueraria lobata Species 0.000 description 5
- 235000010575 Pueraria lobata Nutrition 0.000 description 5
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 5
- 206010039710 Scleroderma Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 201000007930 alcohol dependence Diseases 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000003890 substance P antagonist Substances 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 102000003141 Tachykinin Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 3
- 108060008037 tachykinin Proteins 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical group O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- MECDCHFRZHLREI-PMACEKPBSA-N (2s,3s)-2-benzhydryl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C=1C=CC=CC=1C([C@@H]1N2CCC(CC2)[C@@H]1N)C1=CC=CC=C1 MECDCHFRZHLREI-PMACEKPBSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FPZHOBMVPBJNKL-UHFFFAOYSA-N 2-methoxy-5-propan-2-ylbenzaldehyde Chemical compound COC1=CC=C(C(C)C)C=C1C=O FPZHOBMVPBJNKL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- XCOVQSSCGCJNOA-UHFFFAOYSA-N [Sr].[Ca].[Ca] Chemical compound [Sr].[Ca].[Ca] XCOVQSSCGCJNOA-UHFFFAOYSA-N 0.000 description 1
- KWVFUTDPKIKVQW-UHFFFAOYSA-N [Sr].[Na] Chemical compound [Sr].[Na] KWVFUTDPKIKVQW-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- VEWPBNXVANZNAD-UHFFFAOYSA-N argon sodium Chemical compound [Na].[Ar] VEWPBNXVANZNAD-UHFFFAOYSA-N 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100617 topical lotion Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
A 6 B6 經濟部中央標準局員工消#合作社印製 五、發明説明(1 ) 發明背景 本發明係關於新穎之奎寧衍生物、含此類化合物之藥 學組成物,以及此類化合物在治療與預防炎性和中樞神經 条統疾病,以及數種其他疾病的用途。本發明之具藥學活 力的化合物偽物質P受髖桔抗劑。同時本發明也换關於使 用在合成此類物質P拮抗劑時的新穎中間物。 物質P是一種自然發生的Η--肽(undecapept i de) ,乃屬於速激族(tachykinin family)中的肽,所謂的 速檄族是由於彼等在平滑肌組織上有快速的刺激活動。更 特定言之,物質P僳一藥理學上具活力的神經肽(neuropeptide) , 其是在哺乳動物 中産生 (最先是從腸 中離析 出來的),並且有一特有的氨基酸序列,此乃由美國專利 第4,680, 283 號,D.F. Veber A •所解說。 物質P及其他速激族廣泛地涉入多種疾病的病理生理學已 在此藝中被充份地證實。例如,最近已顯示出物質P牽涉 著疼痛或偏頭痛的傳送(參閲B.E.B. Sandberg ^纟丄., Journal of Medicinal Chemistry. 25, 1009 (1982年)) ,以及牽涉著中樞神經条統病症如焦慮和精神分裂症,也 牽涉有呼吸及炎性疾病例如個別為氣喘及風濕漾關節炎, 和風濕性疾病如纖維織炎,及胃腸病症與GI管道的疾病 如潰瘍性結腸炎與克隆氏症,等。(參閲D. Resoli之> Trends in Cluster Headache , 、、F. S i cuter i e t a 1 -.编 ,Elsevier Scientific出販社,阿姆斯特丹,第85-95 頁(1987年))。 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度遑用中a Η家樣準(CNS)甲4規格(210X297公釐) 一 3 — 81. 5, 20,000(H) Λ ° A < 一
AR 經濟部中央標準局员工消费合作社印製 五、發明説明(2 ) 近來,為了要更有效地治療上文所列之各種疾病及病 症,已做了一些嘗試以提供用於受質P及其他速激肽之拮 抗劑。目前已掲示的少數此類拮抗劑通常在本質上是似一 肽的,所以在疾病的治療上從代謝的觀點來看做為實際的 治療藥劑顯得很不安定。而另一方面,本發明之非一肽拮 抗劑則沒有這個缺點,且從代謝觀點來看會比上文提及之 .試劑更加安定。 本發明之奎寧衍生物有颶類上傜相關於1 9 8 9年 1 1月20日申請之PCT專利申請案PCT/US 89/05338號及199◦年7月23日申請之美國 專利申請案条列第557, 442號,此二者與本申請案 同樣都已讓渡了。其他可展現如物質P受體拮抗劑之活性 的奎寧衍生物乃相關於名為> 3 —胺基一 2 —芳基奎寧" 並在1991年4月25日申請之PCT專利申請案 PCT/US 91/02853號,以及名為''奎寧衍 生物〃並於1 99 1年5月14日申請之PCT專利申請 案PCT/US 92/03369號。這些申請案也與 本申請案同樣都已讓渡了。 發明摘沭 本發明係關於如下式之化合物 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度通用中a國家«準(CNS)甲4規格(210x297公煃) 81. 5. 20.000(H) -4 - Λ 6 Β6
經濟部中央標準局员工消t合作社印製 其中R2表示甲氧基而R2傺個別地選自異丙基、第三一 丁基、甲基、乙基和第二一丁基;以及此類化合物之藥學 上可接受鹽。 本發明之特定化合物包括如: (2S, 3S) —N— (5一異丙基一2一甲氧苯基 )甲基一 2 —二苯基甲基一 1 一氮雜一環〔2. 2〕 辛烷一3 -胺; (2S,3S) — N — (5 一第二一丁基—2一 甲氧 苯基)甲基一2 —二苯基甲基一 1 一氮雜二環〔2. 2〕辛院一 3 —胺; (2S, 3S) —N— (5一甲基一2_甲氧苯基 )甲基一 2 —二苯基甲基_1 一氮雜一環〔2. 2. 2〕 辛烷一 3 —胺; (2S, 3S) — N — (5 一乙玆—2 一甲氧苯基 )甲基一2 —二苯基甲基一1 一氮雜一環〔2· 2· 2〕 辛烷一 3 —胺; (2S, 3S) —N— (5一異丙基一2一甲氧苯基 )甲基_2 —二苯基甲基一1 一氮雜一環〔2. 2. 2〕 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度遑用中國國家標準(CNS)甲4規格(210父297公*) 81. 5_ 20,000(H) -5 一 Μ 經濟部中央標準局貝工消費合作社印製 五、發明説明(4 ) 辛院一 ·3 —胺; (2S, 3S) — Ν - (5 —第二一丁基一 2 — 甲氣 苯基)甲基一2_二苯基甲基一1_氮雜二環〔2. 2. 2〕辛烷一 3 —胺; 以及此類化合物之藥學上可接受的鹽。 本發明同時像關於一種用來治療或預防選自如下狀況 之藥學組成物:哺乳動物(包括人類)中的炎性疾病(如 關節炎、牛皮癣、氣喘及炎性腸疾病)、焦廉、沮喪或心 境惡劣病症、結腸炎、精神病、疼痛、變應性如濕疹和赛 炎、慢性的阻塞性空氣道疾病、過敏性病症如野葛、高血 壓、血管痙孿疾病如咽峽炎、偏頭痛與雷隆氏(Reynaud' s)症、缕維化與膠質性疾病如硬皮病和嗦伊紅白球瓜仁蟲 病、反射交感性營養失調如肩/頭徽候群、有箱病症如酒 精中毒、與壓迫有關之身體病症、周圍神經變性病、神經 病、神經病理學上病症如早老性癡呆病、與AIDS有關 之癡呆、糖尿病的神經變性病與多發性硬化、與免疫提高 或抑制有關之病症如全身性狼瘡紅斑、以及風濕性疾病如 缕維織炎;此組成物包含一能有效治療或預防此類狀況之 量的化學式I化合物或彼之藥學上可接受鹽,及一藥學上 可接受載劑。 本發明同時係關於一種用來治療或預防選自如下狀況 之方法:哺乳動物(包括人類)中的炎性疾病(如關節炎 、牛皮癖、氣喘及炎性腸疾病)、焦慮、沮喪或心境惡劣 病症、結腸炎、精神病、疼痛、變應性如濕疹和鼻炎、慢 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度逍用中國Η家標準(CNS)甲4規格(210x297公;fit) 81. 5. 20.000(H) -6 - 204349 A 6 B6 經濟部中央標準局®C工消費合作社印製 五、發明説明(5 ) 性的阻塞性空氣道疾病、過敏性病症如野葛、高血壓、血 管痙孿疾病如咽峽炎、偏頭痛與雷隆氏(Reynand’ 〇症 、缕維化與膠質性疾病如硬皮病和嗦伊紅白球瓜仁蟲病、 反射交感性營養失調如肩/頭戡候群、有癮病症如酒精中 毒、與壓迫有關之身髏病症、周圍神經變性病、神經病、 神經病理學上病症如早老性窃呆病、與A I DS有關之痪 呆、糖尿病的神經變性病與多發性硬化、與免疫提高或抑 制有閧之病症如全身性狼瘡紅斑、以及風濕性疾病如纖維 鐵炎;此方法包含施藥給該哺乳動物-能有效治療或預防 此類狀況之量的化學式I化合物或彼之藥學上可接受鹽。 本發明同時傺關於一種可拮抗在哺乳動物中(包括人 類)物質P之作用的藥學組成物,其包含一拮抗物質P之 量的化學式I化合物、或彼之藥學上可接受鹽,及一藥學 上可接受載劑。 本發明同時傜關於一種可拮抗在哺乳動物中(包括人 類)物質P之作用的方法,其包含施藥給該哺乳動物一拮 抗物質P之量的化學式I化合物、或彼之藥學上可接受鹽 〇 _ 本發明同時僳關於一種用來治療或預防在哺乳動物中 (包括人類)因物質P過量所導致之病症的藥學組合物, 其包含一拮抗物質P之量的化學式I化合物,或彼之藥學 上可接受鹽,以及一藥學上可接受載劑。 本發明同時係關於一種供治療或預防在哺乳動物中( 包括人類)因物質P過量所導致之病症的方法,其包含一 (請先閲讀背面之注意事項再填窝本頁) 裝. 線· 本紙張尺度逍用中Η B家標準(CNS)甲4規格(210父297公龙) -7 - 81. 5 . 20.000(E) 2〇^349 A6 _ B6 經濟部中央標準局貝工消費合作社印製 五、發明説明(6 ) 拮抗物質P之量的化學式I化合物,或彼之藥學上可接受 鹽。 本發明同時傜醑於一種用來治療或預防選自如下狀況 之藥學組成份:哺乳動物(包括人類)中的炎性疾病(如 開節炎、牛皮癖、氣喘及炎性腸疾病)、焦慮、沮喪或心 境惡劣病症、結腸炎、精神病、疼痛、變應性如濕疹和赛 炎、慢性的阻塞性空氣道疾病、過敏性病症如野葛、高血 壓、血管痙擊疾病如咽峽炎、偏頭痛與雷隆氏(Reynaud’ s)症、缕維化與膠質性疾病如硬皮病和噛伊紅白球瓜仁蟲 病、反射交感性營養失諝如肩/頭戡候群、有«病症如酒 精中毒、與壓迫有閬之身體病症、周圍神經變性病、神經 病、神經病理學上病症如早老性癡呆病、與A IDS有閧 之鉸呆、糖尿病的神經變性病與多發性硬化、與免疫提高 或抑制有關之病症如全身性狼瘡紅斑、以及風濕性疾病如 纖維織炎;此組成物包含一可在其受體位置上有效拮抗物 質P作用之量的化學式I化合物,或彼之藥學上可接受鹽 ,以及一藥學上可接受載劑。 -本發明同時係關於一種供治療或預防選自如下狀況之 方法:哺乳動物(包括人類)中的炎性疾病(如關節炎、 牛皮癖、氣喘及炎性腸疾病)、焦慮、沮喪或心境惡劣病 症、結腸炎、精神病、疼痛、變應性如濕疹和#炎、慢性 的阻塞性空氣道疾病、過敏性病症如野葛、高血壓、血管 痙孿疾病如咽峽炎、偏頭痛與雷隆氏(Reynaud’s)症、纖 維化與膠質性疾病如硬皮病和嗜伊红白球瓜仁蟲病、反射 (請先閲讀背面之注意事項再填寫本頁) 裝· 訂_ 線. 本紙張尺度逍用中國困家標準(CNS)甲4規格(210x297公龙) 81. 5 . 20.000(H) -8 - 204349 A 6 B6 經濟部中央標準局貝工消#合作社印製 五、發明説明(7 ) 交感性營養失調如肩/頭徴候群、有謅病症如酒精中毒、 與壓迫有關之身體病症、周困神經變性病、神經病、神經 病理學上病症如早老性癡呆病、與AIDS有關之癡呆、 糖尿病的神經變性病與多發性硬化、與免疫提高或抑制有 關之病症如全身性狼瘡紅斑、以及風濕性疾病如纗維織炎 ;此方法包含施藥給該哺乳動物可在其受體位置上有效拮 .抗物質P作用之量的化學式I化合物、或彼之藥學上可接 受鹽。 本發明同時僳關於一種用來治療或預防哺乳動物中( 包括人類)之病症的藥學组成物,其中該治療或預防偽藉 由減少物質P居間的神經傳送來進行或促進的,此組成物 包含有一可在其受體位置上有效拮抗物質P作用之量的化 學式I化合物、或彼之藥學上可接受鹽,以及一藥學上可 接受載劑。 本發明同時俗關於一種治療或預防哺乳動物(包括人 類)中之病症的方法,其中該治療或預防係藉由減少物質 P居間的神經傳送來進行或促進的,此方法包含施藥給該 晡乳動物一可在其受體位置上有效拮抗物質P作用之量的 化學式I化合物、或彼之藥學上可接受鹽。 本發明同時係關於一種用來治療或預防哺乳動物(包 括人類)中之病症的藥學組成物,其中該治療或預防俗藉 由減少物質P居間的神經傳送來進行或促進的,此組成物 包含有一能有效治療或預防此病症之量的化學式I化合物 ,或彼之藥學上可接受鹽,以及一藥學上可接受載劑。 (請先閲讀背面之注意事項再填寫本頁) 裝· 訂· 線· 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公婕) 81. 5. 20.000(H) —9 204349 Λ 6 Β6 經濟部中央標準局貝工消费合作社印製 五、發明説明(8 ) 本發明同時僳關於一種治療或預防哺乳動物(包括人 類)中之病症的方法,其中該治療或預防傜藉由減少物質 P居間的神經傳送來進行或促進的,此方法包含有一能有 效治療或預防此病症之董的化學式I化合物,或彼之藥學 上可接受鹽。 本發明之化合物具有對掌中心,所以有不同的對映異 構物型態。本發明僳鬨於化學式I之化合物的所有光學異 構物及所有立體異構物,以及彼等之混合物。 本發明之化合物包括那些與上文所述者相同的化合物 ,但事實上一或多個氫、氮或磺原子可被彼等之同位素( 如氚或硪一 1 4同位素)所取代。此類化合物可使用做為 在代謝藥力學研究上與接合試驗上探討及診斷的工具。探 討中的特定應用包括放射配位基接合試驗。自動放射配位 基研究及活體内接合研究,同時在診斷區域内之特定應用 包括在人類内於炎症相關組織(即免疫一形式細胞或直接 牽涉炎性腸病症及其類似物之細胞)中活體内接合時物質 P受體的研究。 發明說明 本發明之化合物係藉令如下化學式之化合物 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度遑用中國Η家樣準(CNS) T4規格(210x297公龙) 81. 5. 20.000(H) -10 - 204349 Λ 6 Β6
五、發明説明(9 ) och3 II
(具有如該所需之化學式I化合物相同的絶對立膿化學) 水解除去該甲氧苄基以生成如下式之相對應化合物 III
(具有相同之立體化學),然後在一還原劑存在下再令該 所生成之化學式I化合物與如下式之醛反應。 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局员工消費合作社印製 R2
IV 水解除去該甲氧苄基通常是在從約室溫到約該酸的回 流溫度下藉使用一強無機酸如氫氯酸、氫溴酸或氫碘酸來 進行。較佳地,該反應是在回流溫度下於氫溴酸中進行。 此反應經常要進行達約2小時之久。 本紙張尺度通用中國困家標準(CNS)甲4規格(210x297公龙) 81. 5. 20.000(H) -11 - 204349 Λ 6 Β6 經濟部中央標準局员工消t合作社印製 五、發明説明(10) 此外,上述步驟中該甲氣苄基之水解去除作用可由此 基的氫解去除作用取代。氫解去除作用通常會在一含金屬 觸媒如鉛或耙存在下而伴隨著使用氫。此反應經常是在約 0¾到約5 0*0下於一反應惰性溶劑如醋酸或低碩酵中進 行。除此之外,該甲氧苄基也可在溫度從_30它到約 7 8 t:下藉用一溶解之金屬如氨中之鋰或鈉處理該化學式 Π之化合物而被除去,或是在耙存在下用甲酸鹽處理,或 是在耙存在下用環己烷來處理。 較佳地,該甲氧苄基像藉由在約2 5 溫度下於含有 氫氯酸的甲醇中並在披碩氫氧化耙用氫處理該化學式I之 化合物而除去。 該所生成之化學式Μ化合物可在一遢原劑存在下藉與 適當化學式W之醛反應而被轉化成該所需之化學式I化合 物。典型地此反應像在從一 60¾到5〇t:的溫度下藉使 用還原劑如氰基氫硼化鈉、三醋酸基氫硼化鈉、氩硼化鈉 、氫與金屬觸媒、鋅與氫氣酸、硼烷二甲硫或甲酸來進行 。此反應適用之反應惰性溶劑包括低碩醇(如甲醇、乙醇 及異丙醇)、醋酸、二氛甲烷及甲氫呋喃(THF)。較 佳地,該溶劑為二氯甲烷,該溫度是在约25 °C,而該還 原劑是三醋酸基氫硼化鈉。 此外,化學式Μ之化合物與化學式IV之化合物的反應 也可在一乾燥劑存在下或使用一設計有共沸除去所産生之 水的裝備中進行,以生成如下式之亞胺 (請先閲讀背面之注意事項再填寫本頁) 裝. 訂- -線. 本紙張尺度边用中Η B家樣準(CHS)甲4規格(210乂297公龙) -12 - 81. 5. 20.000(H) 204349 五、發明説明(11) R2
然後在約室溫下再與上文提及之還原劑,較佳者為三醋酸 基氫硼化鈉反應。該亞胺之製備通常是在溫度從約2 5t: 到約1 1 Ot:,較佳地約在溶劑的回流溫度下,於一反應 惰性溶剤如苯、二甲苯或甲苯,較佳地是甲苯中進行。合 適之乾燥劑/溶劑糸統包括四氯化鈦/二氣甲烷、異丙醇 酞/二氯甲烷、以及分子篩/THF,而以四氯化鈦/二 氣甲烷較佳。 化學式Μ之化合物也可與下式之適當化合物(其中L 表示離去基,如氯基、溴基、碘基或甲磺醯基)反應而轉 化成具有相同立體化學之化學式I化合物。 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局员工消费合作社印製 R2
此反應通常是在溫度從約0Ό到約6 0Ό,較佳者在約 2 5C下於一反應惰性溶劑如二氣甲烷或T H F,較佳者 為二氯甲烷中進行。 本紙張尺度逍用中國Β家標準(CNS)甲4規格(210x297公釐) 81. 5. 20,000(H) 204349 Λ 6 Β6 五、發明説明(12) 化學式I之化合物也可與如下式之適當化合物 R2
經濟部中央標準局負工消贽合作社印製 (其中L乃如上文所定義者或表示為咪唑)反應,然後再 令該所生成之醛胺還原以轉化成具有相同立體化學之化學 式I化合物。此反應典型地是在約一 20°到約60t:溫 度下於一惰性溶劑如THF或二氛甲烷中進行,而較佳地 是在約ου下於二氯甲烷中進行。還原該生成之醛胺可藉 在惰性溶劑如乙醚或T H F中用還原劑如硼烷二甲硫複合 物、氫化鋁鋰或氫化二異丁基鋁處理而完成。此反應禪度 範圍可從約0Ό到約溶劑的回流溫度。較佳地,該還原反 應俗在約6 Ot下於T H F中使用硼烷二甲硫而完成。 化學式I之新穎化合物及彼之藥學上可接受鹽可使用 做為物質Ρ拮抗劑,亦即彼等在哺乳動物中具有可在其受 體-位置上拮抗物質Ρ作用之能力,所以在受折磨的哺乳動 物中能作用為治療前文提及之病症的治療劑。 本質上為齡性的化學式I之化合物可與無機及有機酸 形成各種不同的鹽。對要施藥給動物而言,雖然此類鹽必 須是藥學上可接受的,但實務上彼通常需要以藥學上不可 接受鹽的形式先從反應混合物中離析出化學式I之化合物 ,然後再藉用一鹼試劑處理以使該藥學上不可接受之鹽能 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度逍用中困Β家標準(CNS)甲4規格(210x297公*) 81. 5. 20.000(H) -14 - 204349 Λ 6 Β6 經濟部中央標準局员工消t合作社印製 五、發明説明(13) 簡易地轉化回自由態碱,隨後再令該自由態碱轉化成一藥 學上可接受鹽。本發明之碱化合物的酸加成鹽可藉在水性 溶劑介質或合適之有機溶劑,如甲醇或乙醇中用一實質上 等量的已選好之無機或有機酸來處理該碱化合物而輕易地 製備。只要小心地蒸發掉溶劑,則該所需之固體鹽即可輕 易得到。 那些本質上也是酸性的化學式I之化合物可與各種藥 理學上可接受之陽離子形成鹼鹽。此類鹽的實例包括鹺金 屬或_土金屬鹽,待定言之為鈉鹽及鉀鹽。這些鹽皆可藉 由已知之技巧製備。該用來做為試劑以製備本發明之藥學 上可接受之鹼鹽的驗是那些可與化學式I、 I及m之化合 物形成無毒性_鹽者。該無毒性鹸鹽包括那些衍生於此藥 理學上可接受之陽離子如鈉、鉀、鈣及鎂等。這些鹽可藉 用一含有該所需之藥理學上可接受陽離子的水溶液來處理 該相對應之酸性化合物,然後再蒸發該所得之溶液至乾燥 (較佳者是在減壓下乾燥)而輕易地製備。此外,這些鹽 也可藉令該酸性化合物之低磺醇溶液與該所需鹼金屬醇鹽 一-起混合,然後再以如前文相同方法蒸發該所得之溶液至 乾燥而製備。在任一情況中最好使用計量化學量的試劑以 便能確定反應的完成及該所需最終産物的最大産量。 化學式I之化合物及彼等之藥學上可接受鹽會抑制物 質p受髏的結合活力,因此在治療與預防種種臨床上狀況 很有價值,該治療或預防俗藉由減低物質p居間的神經傳 送來進行或促進。此類狀況包括炎性疾病(如闋節炎、牛 (請先閱讀背面之注意事項再構寫本頁) 裝. 線< 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公龙) -15 - 81. 5. 20.000(H) 204349 Λ 6 Β6 經濟部中央標準局H3C工消费合作社印製 五、發明説明(14) 皮癣、氣喘及炎性腸疾病)、焦廉、沮喪或心境惡劣病症 、結腸炎、精神病、疼痛、變應性如濕疹和鼻炎、慢性的 阻塞性空氣道疾病、過敏性病症如野葛、高血壓、血管痙 孿疾病如咽峽炎、偏頭痛與雷隆氏(ReynaucTs)症、纖 維化與膠質性疾病如硬皮病和哺伊紅血球瓜仁蟲病、反射 交感性營養失諏如肩/頭戡候群、有《病症如酒精中毒、 與壓迫有關之身體病症、周圍神經變性病、神經病、神經 病理學上病症如甲老性癡呆病、與AIDS有開之癡呆、 糖尿病的神經變性病與多發性硬化、與免疫提高或抑制有 藺之病症如全身性狼瘡紅斑、以及風濕性疾病如纖維織炎 。因此,這些化合物可容易地適用於治療用途上做為物質 P拮抗劑用來控制及/或治療哺乳動物(包括人類)中任 一如前述之臨床狀況。 化學式I之化合物及彼之藥學上可接受鹽傜經由口服 、經腸或局部的路徑來施藥。一般而言,雖然差異會發生 但其端視該受治療主體的體重與狀況以及所選擇的施藥特 別路徑而定,然而這些化合物最需要的服藥劑量範圍是從 約◦. 5毫克到的5 0 0毫克每天。若視受治療的動物種 類及其對該藥劑的個別反應,以及所選擇的藥學調配物型 態和在什麼時間週期與間期下進行施藥而定時,也會發生 差異。在某些例子中,低於前述範圍限度的劑量規定值可 能更適當,然而在其他病況中可能需要較大劑量而不會引 起任何有害的旁反應,只要此較大劑量先分成整天服藥用 的數個小劑量即可。 (請先閱讀背面之注意事項再填寫本頁) 裝< 訂· 線- 本紙張尺度逍用中B國家標準(CNS)甲4規格(210X297公龙) 一 16 一 81. 5. 20,000(H) 204349 經濟部中央標準局貝工消费合作社印製 五、發明説明(15) 本發明之化合物可經由先前所述三種路徑中之一單獨 服用或是與藥學上可接受載劑或稀釋劑組合一起服用。同 時此類服藥可以單一或多次劑量進行。更特定言之,本發 明之新穎治療藥劑可以各種不同的劑量規定形式來服用, 亦即彼等可與多種藥學上可接受之惰性載劑組合而以藥片 、膠囊、錠劑、糖錠、硬糖果、散劑、噴劑、乳霜、油膏 、栓劑、膠凍、凝膠、糊劑、外用藥水、軟膏、水懸浮液 、注射液、酊藥、糖漿、及其類似物形式服用。同時,口 服的藥學組成物可適當地增甜及/或諝味。一般地,本發 明之治療上有效的化合物在此劑量規定形式中的濃度置範 圍在約5 . 0 %到約7 0 %重量比。 對口服施藥而言,含有各種賦形劑如微晶纗維素、檸 檬酸鈉、碩酸鈉、碩酸二鈣及甘氨酸之藥片可與多種分解 劑如澱粉(而較佳地為玉米、馬鈐薯或珍珠粉澱粉)、藻 朊酸及某些複合矽酸鹽一起使用;並伴隨成粒黏合劑如聚 乙烯吡咯烷酮、蔗糖、明膠及阿拉伯膠。此外,潤滑劑如 硬脂酸鎂、月桂基硫酸納及滑石也經常用於製成藥Η的目 时上。在明膠膠囊中之填充劑也可使用類似形態的固體組 成物;在此前後關傺上較佳的物質同時還包括乳糖或牛奶 糖以及高分子量的聚乙二醇。當需要水懸浮液及/或町藥 做為口服方式施藥時,該活性成份可與多種增甜劑或調味 劑、著色物質或染料,以及,若需要的話,還有乳化劑及 /或懸浮劑組合,並伴隨著如水、乙醇、丙二醇、甘油及 多種其類似組合物的稀釋劑。 (請先閲讀背面之注意事項再填寫本頁) 裝. 訂· 線- 本紙ft尺度逍用中國國家標準(CNS)甲4規格(210X297公龙) 81. 5. 20.000(H) -17 - 204349 A6 B6 經濟部中央標準局員工消费合作社印製 五、發明説明(16) 對經腸方式施藥而言,本發明之治療用化合物溶於芝 麻或花生油中或溶於水性丙二醇中之溶液皆可使用。若需 要的話,該水溶液應適當地缓衝(較佳地是pH大於8) 且該液體稀釋劑須先使之等滲壓。這些水溶液乃適用於靜 脈内注射目的。該油性溶液則適用於.閧節内、肌肉内及皮 下的注射目的。所有這些溶液在無菌下的製備都可藉熟諳 此蓊者已知之標準製藥技巧而軽易完成。 再者,當欲治療皮虜的炎性狀況時以局部方式施以本 發明之化合物也是可行的,而較佳地此舉將根據標準的藥 學實務藉由乳霜、膠凍、凝膠、糊劑、軟膏及其類似物來 進行。 本發明之化合物其做為物質P拮抗劑的活力可經由彼 等於牛尾狀組織中在其受體位置上抑制物質P接合的能力 ,以及藉放射照相術並使用放射性配位基以使該速激受體 看得見而測得。本文所述化合物之物質P拮抗活力可藉用 由 M.A. Cascieri e t al.,在 Journal of Biological C~ hemi stry,Vo 1 · 258卷,第5158頁 (1983年)中所報告之 檫準鑑定步驟來評估。此方法實質上包括了測置在該已離 析母牛組織中欲減少5 0%量之在其受體位置上有放射標 記的物質P配位基時所需要的個別化合物濃度,藉以提供 每一欲試驗化合物有特徴的IC〃值。 在此步驟中,牛尾狀組織是從一 70t:冰凍室中取出 ,並在50體積份(w. /v.)的冰冷50毫莫耳催素 (Tris)(亦即表示為2—胺基一2_羥甲基二1, (請先閲讀背面之注意事項再填寫本頁) 裝· 訂 本紙張尺度逍用中國國家標準(CNS)甲4規格(210X297公*) -18 - 81. 5. 20.000(H) 2〇4349 Λ6 B6 經濟部中央標準局貝工消费合作社印製 五、發明説明(17) 3 —丙二醇之三甲胺)之氫氛化物缓衝剤(pH為7. 7 )中勻化。在30, OOOXG下離心該勻漿達20分鐘 。令該九粒再懸浮於50體積份的Tr i s缓衝劑中,並 再勻化,然後在30, 000XG下再離心達另一餾20 分鐘。然後該九粒懸浮於40體積份之含有2毫其耳氯化 鈣、2毫莫耳氣化鎂、40克/毫升菌桿肽素、4撤克/ 毫升亮肽素、2微克抑糜蛋白酶素及200克/毫升牛血 清蛋白的冰冷50毫莫耳Tr i s緩衝劑(pH7. 7) 中。此階段可完成組織製劑的製造。 接著,放射配位基結合步驟乃以如下方法進行,亦即 經由添加100微升之試驗化合物使濃度成為1微莫耳來 啓動反應,接著再添加100徹升放射性配位基使最終濃 度為0. 5毫莫耳,而最後再加入800撤升如上文所述 而製得之組織製劑。因此最終體積為1. 0毫升,接下來 則在室溫下將該反應混合物渦旋共置2◦分鐘之久。然後 用細胞收集器過濾該試管,並以5 0毫莫耳催素( Tr i s)缓衝劑(ρΗ7· 7)清洗玻璃纖維濾器( Whatman GF/B) 4次,該濾器在過濾步驟之前已先預浸濕 2小時之久。然後在一 Beta計數器中以5 3 %計數效率測 量放射性,而該IC5。是藉用標準的統計方法計算。 本發明之化合物僳做為致類神經病症狀劑以控制各種 神經病症的抗一神經病活力,主要地可藉研究彼等抑制天 竺鼠中由物質P—誘發或物質P催動肌誘發的蓮動過強之 能力來判斷。此研究首先須用一控制化合物或用本發明之 (請先閲讀背面之注意事項再蜞寫本頁) 裝. 訂. 線. 本紙張尺度逍用中國B家楳準(CNS)甲4規格(210x297公龙) -19 _ 81. 5. 20,000(H) ^0^49_II_ 五、發明説明(18) 適當的試驗化合物令天竺鼠服下,然後以大腦内施藥方式 經由套管將物質p或物質p催動肌注射入該天竺鼠中,其 後測量他們對該剌激物的値別蓮動反應。 本發明將藉由下列實施例解説。然而,可以明瞭的是 本發明並不會受這些實施例的待定說明所限制。 奮掄例1 (2 S . 3 S ) — N - ( 5 -異丙基一 2 -申董荣某)甲 甚一 2_二茱某甲某_1 _氤雜一二瑗[2. 2. 2Ί辛 烷一2—胺甲磋酴皤 A . ( 2 S . 3 S ) — 2 -(2 -二苯基甲基)—1 一钪雜二璟「2. 2. 2]辛烷一 3 —胺_ 在室溫下於甲醇(MeOH) (4 ◦毫升)/6N氫 氯酸(HC5) (10毫升)中藉使用20%披碩氫氧化 耙並以2. 5公斤/平方公分氫令(2S, 3S) — N-(2_甲氣苯基)甲基一 1 一氮雜二環〔2. 2. 2〕一 辛烷_3_胺(4. 12克,10毫莫耳)氫化達60小 經濟部中央標準局員工消费合作社印製 (請先閱讀背面之注意事項再填寫本頁) 時。過濾該反應物並濃縮該濾出液,則可得到粗槌産物, 其可從乙醇中再結晶。 B . (2S, 3S) — N — (5 -異丙甚一?· 一甲氲 荣甚)田甚一 2 —二苯基甲基一1 一氙雜二瑄「2. 2. 壬烷一3 —胺甲礒酸鹽 將三醋酸基氫硼化物逐部份地加入於一含有5 —異丙 基一 2_甲氧基苯甲醒(7 48笔:克,4·. 2毫莫耳)及 本紙張尺度通用中《國家標準(CNS)甲4規格(210><297公逄) -20 - 81. 5. 20.000(H) Λ6 Β6 五、發明説明(19) (2S, 3S) — 2 —二苯基甲基_1—氮雜二環〔2. 2. 2〕一辛烷一 3 —胺(4毫莫耳)之二氣甲烷( C H 2C )? ,) (40毫升)溶液中。攪拌該混合物直至胺 消失為止。用冰冷飽和之碩酸氫鈉(NaHC〇3 )溶液 小心地中和該溶液。用水清洗該有機層,並用硫酸鎂( Mg SCU )乾燥之,然後濃縮至可得到産物(1. 82 克)為止。加入相等量甲磺酸於該産物之丙酮溶液中。然 後收集已沈澱之甲磺酸鹽並在真空下乾燥。 實施例2—5之標題化合物可藉由類似於實施例1之 步驟來製備。 奮施例2 (2 S · 3 S ) - N — ( 5 —甲基一 2 一甲氣笨基) 申甚一2—二茱某甲基一1一氤雜一二瑗Γ2. 2. 21 辛烷一3—胺甲磋酴鹽 M . p . : 2 4 0 t: 經濟部中央標準局员工消费合作社印製 I R (KBr) 〇]11-2:341〇, 2980, 1-640, 1 5 0 0, 1 4 5 5, 1200, 1060, 7 10〇 NMR (CDC13) δ: 7.5-7.2(10H,m), 7.10(lH,m)8.40(lH,br), 6 . 63 ( 1 Η , d , J = 8 Η ζ ), 6 . 3 9 ( 1 Η , b r s ), 81. 5. 20.000(H) (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度遑用中國B家標準(CNS)甲4規格(210x297公釐) -21 - 9 43 420 66 ΛΒ 五、發明説明(20) 4. 55(lH,m)4.12(lH,m), ο s m m 6 3 » » » 1.Η Η Η . 3 3 112 I /TV /TV /|\ I 0 3 0 2 0 8 5 2 4 3 ·«♦♦· 3 3 3 2 2 Η 3 2 2 Η 5 , , , 4 )571 m 2 4 2 m mss 9 9 9Η Η Η 13 3 3 例 施 奮 S 3 S 2
N 5 基 苯 氩甲 - 2 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央榣準扃tac工消费合作社印製 甲某一2 —二茱基甲某一 1—氤雜二環Γ2. 2. 21辛 院一3—胺甲磋酸輔 M . p . : 1 5 1 t: I R ( K B r ) cm_i: 3420,2970, 1640, 1 5 1 0, 1 4 6 0, 1195, 1 0 6 0, 7 8 5 〇 'Η Ν Μ R ( C D C 1 3) δ : 98568754 .1 8 8 6 5 0 2 o······· 18766554
r b H
r b , H 1X 5 m d b 1X f 9 9 .Η Η H 7. '~~_ -~~- 1x
H m
J r 8 5 H 5 8 4 z
H m z H 2 , • ) 3 m 1 , II H J 5 /v d 5 ,6 H . 1 3 81. 5. 20.000(H) 本紙張尺度逍用中a Η家標準(CNS)甲4規格(210x297公泄) -22 -
66 ΛΒ 五、發明説明(21) 3 . 4 8 ( 3 H , s ), Η 2 m 3 . , ίΛ τπ. ίχ \1/ ΤΓ* \J )/ 5 m 6 m ο m 3 * ( ,8 , .Η 2 Η .Η 3 1 .213 -(2(-( 02 I40 1 5 9 8 5 3 2 3 2 2 2 2 1 m 6 Η 6
S Η 2 ο m 4 例 施 奮 S 3 S 2
2 I 某 丙 異- 5 /1- N 某 苯 氩 甲 (請先閲讀背面之注意事項再填寫本頁) ¾ 基 苯二 1 2 1 基 甲 2 環二 雜 辛烷_3_胺甲磋酸鹽 M . p . : 2 2 I t: 1 R ( K B r ) cm'2: 3430, 2960, 1 6 0 0, 1 5 0 0, 1 4 5 5, 1245, 1 1 6 0 1 0 4 0,7 1 0。 2 H NMR (CDCla) δ : 裝. 訂 線 經濟部中央標準局貝工消赀合作社印製 H 2 Η Η Η H 3 1± · 1—I -—- 1± -—- · (7((((3 οI 6 7 6 8 一 4 5 0 6 5 5 6 8 7 7 6 6 4 3 Γη f )Η r 〇 ID 1 z H 4 • 8 = , J \«/ » m d s 4 m t 9 t r ) H b m 5 4 2
H m 本紙張尺度边用中國B家標準(CNS)甲4規格(210X297公龙) 81. 5. 20,000(H) -23 -
66 ΛΒ 五、發明説明(22) 3 . 5 3 ( 3 H , s ) 9 3 • 2 4 ( 1 H, m ), 3 . 2 2 ( 1 H , m ) t 2 . 7 8 ( 1 H , s e P 9 J = 7 H z ), 2 . 4 8 ( 4 H , s ) t 2 • 4 2 ( 1 H , m ), 2 . 2 7 ( 1 H , m ) > 1 • 9 9 ( 2 H , m ), 1 . 7 6 ( 1 H , m ) t 1 . 2 0 ( 6 H , d d 9 J = 2 9 H z , 7 H 2 〇 奮施例5 (2S. 3 S) —N - (5 —笛二一丁某一2 — 甲氬 C荣基)田甚一 P. —二荣甚甲甚一 1_氤雜二環Γ2. 2.
2Ί辛烷—胺甲磋酴鹽Μ . p . : 2 2 4 V .............. i (請先閲讀背面之注意事項再填寫本頁) 裝. 訂_ 經濟部中央標準局员工消費合作社印製 I R ( Κ Β r ) c m -I 3 4 4 〇 t 2 9 6 0 1 6 1 〇 1 1 5 0 〇 f 1 4 5 5 t 1 2 2 〇 » 1 1 1 0 3 5 9 7 5 5 9 7 1 〇 9 5 6 0 〇 - 2 Η Ν Μ R ( c D C 1 3 ) δ 8 4 1 ( 1 H 9 b r ) > 7 5 — 7 • 2 ( 1 〇 H 9 m ) 1 7 〇 〇 ( 1 H 9 m ) 9 6 6 7 ( 1 H 9 d 9 J = 8 • 4 H z ) 9 6 5 2 ( 1 H 9 b Γ 9 s ) 4 5 8 ( 1 H f d f J — 1 1 7 H z ) 9 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公;¢) 81. 5. 20.000(H) -24 204¾49 Λ 6 Β6 經濟部中央標準局员工消赀合作社印製 五、發明説明(23) 4 . 2 5 ( 1 Η 9 m ) t 3 . 7 0 — 3 • 3 5 (5 H , m ) t 3 . 5 3 ( 3 Η > s ) f 3 . 2 1 (2 H , m ), 2 . 4 6 ( 3 Η > s ) t 2 . 4 3 ( 1 H , m ), 2 . 2 6 ( 1 Η m ) t 2 . 0 4 ( 1 H , m ), 2 . 〇 0 — 1 • 6 0 (3 H , m ) > 1 . 5 2 ( 2 Η $ m ) 1 . 1 8 ( 2 H , m ), 0 . 8 2 ( 3 Η t m ) 〇 (請先閲讀背面之注意事項再填寫本頁) 裝. 線. f紙張尺度通用中國Β家標準(CNS)甲4規格(210X297公龙) 81. 5. 20,000 (H) -25
Claims (1)
- 本 A7 B7 C7 D7 六、申請專利範® 附件一 A : 第81103509號專利申請案 中文申請專利範圍修正本 民國82年3月修正 vl . —種如下式之化合物 R2(請先Μ讀背面之注竞事項再填寫本頁) •裝. 經濟部十央標準局貝工消费合作社印製 其中R2表示甲氣基而R2僳選自異丙基、第三一丁基、 甲基、乙基及第二一丁基;以及此化合物之藥學上可接受 鹽。 2.如申請專利範圍第1項之化合物,其中該化合物 偽選自: (2S, 3S) — N — (5 —異丙基一 2 —甲氣苯基 )甲基一2 —二苯基甲基一1 一氮雜二環〔2. 2. 2〕 辛烷—3 -胺; (2S, 3S) —N — (5 —甲基一2 —甲氧苯基 )甲基一2—二苯基甲基一1一氮雜二環〔2. 2. 2〕 辛烷一 3 —胺; (2S, 3S) —N— (5—乙基一2—甲氧苯基 )甲基一 2 —二苯基甲基一1 一氤雜二環〔2. 2. 2〕 本紙張尺度適用中囲國家搮毕(CNS)肀4規格(210x297公*) _________07 C7 經浒部屮央標準屈負工消贽合作社印^ 六、申請專利範園 辛院一 3 —胺; (2S, 3S) —N— (5—異丙基一2—甲氧苯基 )甲基一.2-二苯基甲基_1 一氮雜二環〔2. 2. 2〕 辛烷一 3 —胺; (2S, 3S) — N — (5 —第三一丁基一2 —甲氧 苯基)'甲基一 2 —二苯基甲基一 1 一氮雜二環〔2. 2. 2〕辛烷一 3 —胺; (2S, 3S) — N — (5-第二一丁基一2 — 甲氣 苯基)甲基一 2 —二苯基甲基一 1 一氮雜二環〔2. 2. 2〕辛烷一 3 —胺; 以及此類化合物之藥學上可接受鹽。 3. (2S,3S)— N — (5 —異丙基一2 —甲氣 苯基)甲基一2 —二苯基甲基一1 一氮雜二環〔2 . 2 . 2〕辛烷—3 —胺甲磺酸鹽。 4. 一種用來治療或預防選自如下疾病之藥學組成物 ,其中該治療或預防像藉由減少物質P居間的神經傳送來 進行或促進的,該疾病僳選自:哺乳動物中的炎性疾病、 焦慮、結腸炎、沮喪或心境惡劣病症、精神病、疼痛、變 應性、慢性的阻塞性呼吸道疾病、過敏性病症、高血壓、 血管痙孿疾病、纖維化與膠質性疾病、反射交感性營養失 調、有箱病症、與壓迫有關之身體病症、周圍神經變性病 、神經病、神經病理學上病症、與免疫提高或抑制有關之 病症、以及風濕性疾病,此藥學組成物包含一治療或預防 此狀況之有效劑量的如申請專利範圍第1項之化合物以及 (請先閱讀背面之注意事項再填坧本百} 本纸張尺度適用中國國家橾準(CNS)甲4規格(210X297公嫠) -2 - 204⑽ A7 B7 C7 D7 六、申請專利範園 一藥學上可接受載劑。 5. —種用來拮抗哺乳動物中物質P之作用的藥學組 成物,其包含一可拮抗物質P之有效量的如申請專利範圍 第1項之化合物及一藥學上可接受載劑。 6. —種用來治療或預防哺乳動物中之病症狀況的藥 學組成物,其中該治療或預防像藉由減少物質P居間的神 經傳送來進行或促進的,此組成物包含一可在其受體位置 上有效拮抗物質P作用之量的如申請專利範圍第1項之化 合物及一藥學上可接受載劑。 V.—種用來治療或預防哺乳動物中之病症狀況的 藥學組成物,其中該治療或預防傺藉由減少物質P居間的 神經傳送來進行或促進的,此組成物包括一可有效治療或 預防此狀況之量的如申請專利範圍第1項之化合物、或彼 之藥學上可接受鹽,以及一藥學上可接受載劑。 8. (2S,3S)-N-(5 —異丙基一2-甲氣 苯基)甲基一2—二苯基甲基一1一氮雜一二環〔2. 2 .2〕辛烷_3_胺之二氫氯化物。 (請先聞請背面之注意事項再填寫本頁) ♦发· 經漪部屮央標準局貝工消费合作社印製 •線· 本纸》尺度適用中國國家標準(CNS)甲4規格(210x297公釐) -3 - g\ iv 〇04349 _ 附件二 第81103509號專利申請案 中文補充藥理·試驗 民國81年11月呈X IM-9 天竺鼠輸尿管測定法 結合性 IC50 IlM EDS0 mg/kg Me 0.08 0.1 Et 0.09 0.01 i-Pr 0.04 0.02 t-BU 0.03 s-Bu 0.05 1 204349 CaPSa 1C 1 πΡ/f ffn.4彥夕卜 {乍 (d 1 ^xt^.r'avagT^'l-. i on) 血#焚外潘作用i系以腹腔内注射capsa ic i n (含有30/om capsaicin溶液之10毫升〇. 1% BS A/生理食捏水)至經 s Pentobarbitol麻醉的天竺鼠(25毫克/公斤、腹腔内注 射)而誘導的。將待測化合物溶於0.1%甲基纖維素一水 且於capsaicin施用前1小時口服投藥。 capsa ic ia方在用前 5分鐘,血管内注射均句藍色染料(30毫克/公斤)。10 分鐘後,殺死天竺鼠,移除背部皮*,使用軟木塞鐵孔器 (11.5毫米口徑)挑出藍點。 〇 其組織之染料含童經過甲醯胺萃取一夜之後,於600nm吸 光度下定量。 ▼ 4 (219X297公 Μ >
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70840491A | 1991-05-31 | 1991-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW204349B true TW204349B (zh) | 1993-04-21 |
Family
ID=24845673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW081103509A TW204349B (zh) | 1991-05-31 | 1992-05-05 |
Country Status (41)
| Country | Link |
|---|---|
| US (3) | US5807867A (zh) |
| EP (1) | EP0587723B1 (zh) |
| JP (2) | JPH0733386B2 (zh) |
| KR (1) | KR100214905B1 (zh) |
| CN (1) | CN1048492C (zh) |
| AP (1) | AP299A (zh) |
| AT (1) | ATE135006T1 (zh) |
| AU (1) | AU657552B2 (zh) |
| BG (1) | BG61694B1 (zh) |
| BR (1) | BR9206073A (zh) |
| CA (1) | CA2102179C (zh) |
| CZ (1) | CZ281403B6 (zh) |
| DE (4) | DE9290063U1 (zh) |
| DK (1) | DK0587723T3 (zh) |
| EG (1) | EG19944A (zh) |
| ES (1) | ES2084361T3 (zh) |
| FI (1) | FI114475B (zh) |
| GR (1) | GR3019687T3 (zh) |
| GT (1) | GT199200028A (zh) |
| HU (1) | HU217548B (zh) |
| IE (1) | IE72473B1 (zh) |
| IL (1) | IL102008A (zh) |
| IS (1) | IS1611B (zh) |
| LU (1) | LU91293I2 (zh) |
| MA (1) | MA22539A1 (zh) |
| MX (1) | MX9202554A (zh) |
| NL (1) | NL300250I2 (zh) |
| NO (2) | NO302701B1 (zh) |
| NZ (2) | NZ270673A (zh) |
| OA (1) | OA09867A (zh) |
| PL (1) | PL171379B1 (zh) |
| PT (1) | PT100546B (zh) |
| RO (1) | RO110499B1 (zh) |
| RU (1) | RU2103269C1 (zh) |
| SK (1) | SK390692A3 (zh) |
| TW (1) | TW204349B (zh) |
| UA (1) | UA27776C2 (zh) |
| UY (1) | UY23422A1 (zh) |
| WO (1) | WO1992021677A1 (zh) |
| YU (1) | YU48995B (zh) |
| ZA (1) | ZA923942B (zh) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9290063U1 (de) * | 1991-05-31 | 1994-02-24 | Pfizer Inc., New York, N.Y. | Chinuclidin-Derivate |
| UA39168C2 (uk) * | 1991-06-20 | 2001-06-15 | Пфайзер, Інк. | Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі |
| ATE208376T1 (de) * | 1992-08-19 | 2001-11-15 | Pfizer | Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen |
| ATE147385T1 (de) * | 1992-11-12 | 1997-01-15 | Pfizer | Chinuclidin derivat als substanz p antagonist |
| US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| IL109646A0 (en) * | 1993-05-19 | 1994-08-26 | Pfizer | Heteroatom substituted alkyl benzylamino-quinuclidines |
| JP2822274B2 (ja) * | 1993-05-19 | 1998-11-11 | ファイザー製薬株式会社 | P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類 |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Substance P antagonists for the treatment or prevention of sunburn. |
| EP0659409A3 (en) * | 1993-11-23 | 1995-08-09 | Pfizer | Substance P antagonists for the inhibition of angiogenesis. |
| EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| PE8798A1 (es) * | 1995-07-17 | 1998-03-02 | Pfizer | Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil] |
| TW458774B (en) | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
| IL123740A0 (en) * | 1997-03-28 | 1998-10-30 | Pfizer | NK-1 receptor antagonists for the treatment of delayed emesis |
| NZ329807A (en) * | 1997-04-23 | 2000-07-28 | Pfizer | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome |
| ID25818A (id) * | 1998-03-19 | 2000-11-09 | Takeda Chemical Industries Ltd | Senyawa-senyawa heterosiklik, produksinya dan penggunaannya |
| US6255320B1 (en) * | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| US6387925B1 (en) * | 1999-06-01 | 2002-05-14 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions |
| US6262067B1 (en) * | 1999-06-22 | 2001-07-17 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions |
| JP2001172178A (ja) * | 1999-10-25 | 2001-06-26 | Pfizer Prod Inc | 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン |
| DK1246806T3 (da) | 1999-11-03 | 2008-06-16 | Amr Technology Inc | Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| IL142810A0 (en) * | 2000-05-03 | 2002-03-10 | Pfizer Prod Inc | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles |
| WO2002004455A2 (en) | 2000-07-11 | 2002-01-17 | Albany Molecular Research, Inc | 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| JP2005504029A (ja) * | 2001-07-20 | 2005-02-10 | ファイザー・プロダクツ・インク | 犬の好ましくない行動を改善するためのnk−1受容体アンタゴニストの使用 |
| US6686507B2 (en) | 2002-03-06 | 2004-02-03 | Pfizer Inc | Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde |
| GB0220581D0 (en) * | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| WO2004064717A2 (en) * | 2003-01-21 | 2004-08-05 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
| US20050136487A1 (en) * | 2003-10-27 | 2005-06-23 | Meyer Donald W. | Transmissible spongiform encephalopathy detection in cervids, sheep and goats |
| DE602004028150D1 (de) * | 2003-11-26 | 2010-08-26 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
| CA2554346C (en) * | 2004-01-30 | 2009-11-17 | Pfizer Products Inc. | Parenteral formulations comprising a beta-cyclodextrin and a preservative |
| CN1913893A (zh) | 2004-01-30 | 2007-02-14 | 辉瑞产品有限公司 | 改善麻醉恢复的nk-1受体拮抗剂 |
| BRPI0507334A (pt) | 2004-02-02 | 2007-07-03 | Pfizer Prod Inc | processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina |
| KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| NZ565111A (en) | 2005-07-15 | 2011-10-28 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| JP5489333B2 (ja) | 2006-09-22 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 脂肪酸合成阻害剤を用いた治療の方法 |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| CA2674436C (en) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| AU2008208920A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1 |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| ES2528404T3 (es) | 2009-05-12 | 2015-02-10 | Bristol-Myers Squibb Company | Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos |
| AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
| US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| HRP20191232T1 (hr) | 2010-08-17 | 2019-11-01 | Sirna Therapeutics Inc | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| AU2012245455A1 (en) | 2011-04-21 | 2013-10-31 | Merck Sharp & Dohme Corp. | Insulin-Like Growth Factor-1 Receptor inhibitors |
| ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Erk阻害剤である新規化合物 |
| HK1215170A1 (zh) | 2012-11-14 | 2016-08-19 | The Johns Hopkins University | 治療精神分裂症的方法和組合物 |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| CN106977512B (zh) * | 2017-05-04 | 2019-01-01 | 海门慧聚药业有限公司 | 制备马罗匹坦游离碱的方法 |
| KR20200026920A (ko) | 2017-06-30 | 2020-03-11 | 체이스 테라퓨틱스 코포레이션 | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
| KR102102109B1 (ko) * | 2018-07-10 | 2020-04-20 | 성균관대학교산학협력단 | N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물 |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| CN112805006B (zh) | 2018-08-07 | 2024-09-24 | 默沙东有限责任公司 | Prmt5抑制剂 |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP4117673A1 (en) | 2020-03-11 | 2023-01-18 | Ospedale San Raffaele S.r.l. | Treatment of stem cell deficiency |
| AT527172A1 (de) | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| AU648317B2 (en) * | 1990-06-01 | 1994-04-21 | Pfizer Inc. | 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them |
| DE4026743A1 (de) * | 1990-08-24 | 1992-02-27 | Teves Gmbh Alfred | Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge |
| US5716965A (en) * | 1991-05-22 | 1998-02-10 | Pfizer Inc. | Substituted 3-aminoquinuclidines |
| DE9290063U1 (de) * | 1991-05-31 | 1994-02-24 | Pfizer Inc., New York, N.Y. | Chinuclidin-Derivate |
| ATE195867T1 (de) * | 1991-09-20 | 2000-09-15 | Glaxo Group Ltd | Neue medizinische indikation für tachykinin- antagonisten |
| GB9218334D0 (en) * | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
| US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
| PT785198E (pt) * | 1996-01-19 | 2000-11-30 | Lonza Ag | Processo para a producao de 3-quinuclidinol opticamente activo. |
| US5990125A (en) * | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
-
1992
- 1992-04-28 DE DE9290063U patent/DE9290063U1/de not_active Expired - Lifetime
- 1992-04-28 BR BR9206073A patent/BR9206073A/pt not_active Application Discontinuation
- 1992-04-28 RU RU93058555A patent/RU2103269C1/ru active Protection Beyond IP Right Term
- 1992-04-28 AU AU19901/92A patent/AU657552B2/en not_active Expired
- 1992-04-28 CA CA002102179A patent/CA2102179C/en not_active Expired - Lifetime
- 1992-04-28 DE DE200612000066 patent/DE122006000066I2/de active Active
- 1992-04-28 DE DE69208877T patent/DE69208877T2/de not_active Expired - Lifetime
- 1992-04-28 DK DK92912601.9T patent/DK0587723T3/da active
- 1992-04-28 EP EP92912601A patent/EP0587723B1/en not_active Expired - Lifetime
- 1992-04-28 CZ CS923906A patent/CZ281403B6/cs not_active IP Right Cessation
- 1992-04-28 UA UA93004096A patent/UA27776C2/uk unknown
- 1992-04-28 RO RO93-01581A patent/RO110499B1/ro unknown
- 1992-04-28 AT AT92912601T patent/ATE135006T1/de active
- 1992-04-28 US US08/211,120 patent/US5807867A/en not_active Expired - Lifetime
- 1992-04-28 JP JP5500353A patent/JPH0733386B2/ja not_active Expired - Lifetime
- 1992-04-28 DE DE1992608877 patent/DE122006000066I1/de active Pending
- 1992-04-28 SK SK3906-92A patent/SK390692A3/sk not_active IP Right Cessation
- 1992-04-28 HU HU9303393A patent/HU217548B/hu active Protection Beyond IP Right Term
- 1992-04-28 WO PCT/US1992/003317 patent/WO1992021677A1/en not_active Ceased
- 1992-04-28 PL PL92301472A patent/PL171379B1/pl unknown
- 1992-04-28 KR KR1019930703649A patent/KR100214905B1/ko not_active Expired - Lifetime
- 1992-04-28 ES ES92912601T patent/ES2084361T3/es not_active Expired - Lifetime
- 1992-05-05 TW TW081103509A patent/TW204349B/zh not_active IP Right Cessation
- 1992-05-11 AP APAP/P/1992/000384A patent/AP299A/en active
- 1992-05-26 IL IL10200892A patent/IL102008A/en active Protection Beyond IP Right Term
- 1992-05-26 UY UY23422A patent/UY23422A1/es not_active IP Right Cessation
- 1992-05-29 IS IS3871A patent/IS1611B/is unknown
- 1992-05-29 ZA ZA923942A patent/ZA923942B/xx unknown
- 1992-05-29 NZ NZ270673A patent/NZ270673A/en not_active IP Right Cessation
- 1992-05-29 YU YU56492A patent/YU48995B/sh unknown
- 1992-05-29 NZ NZ242956A patent/NZ242956A/en not_active IP Right Cessation
- 1992-05-29 MX MX9202554A patent/MX9202554A/es unknown
- 1992-05-29 PT PT100546A patent/PT100546B/pt not_active IP Right Cessation
- 1992-05-29 GT GT199200028A patent/GT199200028A/es unknown
- 1992-05-29 MA MA22826A patent/MA22539A1/fr unknown
- 1992-05-30 EG EG28492A patent/EG19944A/xx active
- 1992-05-30 CN CN92104129A patent/CN1048492C/zh not_active Expired - Lifetime
- 1992-07-01 IE IE921729A patent/IE72473B1/en not_active IP Right Cessation
-
1993
- 1993-11-26 BG BG98248A patent/BG61694B1/bg unknown
- 1993-11-29 NO NO934312A patent/NO302701B1/no not_active IP Right Cessation
- 1993-11-29 FI FI935297A patent/FI114475B/fi not_active IP Right Cessation
- 1993-11-30 OA OA60442A patent/OA09867A/en unknown
-
1994
- 1994-10-05 JP JP6241456A patent/JP2645225B2/ja not_active Expired - Lifetime
-
1995
- 1995-01-24 US US08/377,552 patent/US6222038B1/en not_active Expired - Lifetime
-
1996
- 1996-04-19 GR GR960401066T patent/GR3019687T3/el unknown
-
1997
- 1997-04-30 US US08/846,909 patent/US5939433A/en not_active Expired - Lifetime
-
2006
- 2006-12-06 LU LU91293C patent/LU91293I2/fr unknown
- 2006-12-06 NL NL300250C patent/NL300250I2/nl unknown
-
2007
- 2007-03-09 NO NO2007003C patent/NO2007003I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW204349B (zh) | ||
| EP0668863B1 (en) | Quinuclidine derivative as substance p antagonist | |
| US7122675B2 (en) | Gamma secretase inhibitors | |
| US20070254915A1 (en) | Cxcr4 modulators | |
| US7579471B2 (en) | Tropane derivatives useful in therapy | |
| US9440953B2 (en) | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors | |
| JP2001522846A (ja) | アザ環−エーテル誘導体及びこれをニコチン性achレセプターモジュレーターとして使用する方法 | |
| JP2007532601A (ja) | 選択されたcgrp−拮抗薬、その調製方法および薬剤としてのその使用 | |
| US20240197678A1 (en) | Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof | |
| CN116535390B (zh) | pH敏感型4-酰胺哌啶类衍生物、药物组合物及其制备方法和应用 | |
| EP1323713A1 (en) | 5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis | |
| US20250066383A1 (en) | Pde 7 modulator compounds | |
| US20080070898A1 (en) | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | |
| JP2022537291A (ja) | ヘテロ環式誘導体及びその使用 | |
| HK1054744A (zh) | 5-苯基苄胺化合物、其制备方法和用於其合成的中间体 | |
| HK1000246A1 (zh) | 用作p物质抗剂的奎核抗剂 | |
| HK1000246B (zh) | 用作p物质抗剂的奎核抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |